130 related articles for article (PubMed ID: 25449106)
21. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
[TBL] [Abstract][Full Text] [Related]
22. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
[TBL] [Abstract][Full Text] [Related]
23. Somatically mutated regions of immunoglobulin on human B-cell lymphomas code for peptides that bind to autologous major histocompatibility complex class I, providing a potential target for cytotoxic T cells.
Gricks CS; Rawlings E; Foroni L; Madrigal JA; Amlot PL
Cancer Res; 2001 Jul; 61(13):5145-52. PubMed ID: 11431353
[TBL] [Abstract][Full Text] [Related]
24. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
25. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.
Tsuji T; Matsuzaki J; Caballero OL; Jungbluth AA; Ritter G; Odunsi K; Old LJ; Gnjatic S
J Immunol; 2012 Apr; 188(8):3851-8. PubMed ID: 22427632
[TBL] [Abstract][Full Text] [Related]
26. Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.
Chen F; Fan C; Gu X; Zhang H; Liu Q; Gao X; Lu J; He B; Lai X
Med Sci Monit; 2015 Jul; 21():2110-5. PubMed ID: 26195067
[TBL] [Abstract][Full Text] [Related]
27. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
[TBL] [Abstract][Full Text] [Related]
28. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
[TBL] [Abstract][Full Text] [Related]
29. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
[TBL] [Abstract][Full Text] [Related]
30. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999.
Grillo-López AJ; Kunkel L
Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464
[No Abstract] [Full Text] [Related]
31. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
32. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
Weng J; Rawal S; Chu F; Park HJ; Sharma R; Delgado DA; Fayad L; Fanale M; Romaguera J; Luong A; Kwak LW; Neelapu SS
Blood; 2012 Aug; 120(8):1613-23. PubMed ID: 22645177
[TBL] [Abstract][Full Text] [Related]
33. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.
Chu Y; Hochberg J; Yahr A; Ayello J; van de Ven C; Barth M; Czuczman M; Cairo MS
Cancer Immunol Res; 2015 Apr; 3(4):333-44. PubMed ID: 25492700
[TBL] [Abstract][Full Text] [Related]
34. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
[TBL] [Abstract][Full Text] [Related]
35. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
[TBL] [Abstract][Full Text] [Related]
36. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
37. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
[TBL] [Abstract][Full Text] [Related]
38. Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients.
Milcent B; Josseaume N; Riller Q; Giglioli I; Rabia E; Deligne C; Latouche JB; Hamieh M; Couture A; Toutirais O; Lone YC; Jeger-Madiot R; Graff-Dubois S; Amorim S; Loiseau P; Toubert A; Brice P; Thieblemont C; Teillaud JL; Sibéril S
Cancer Immunol Immunother; 2019 Oct; 68(10):1561-1572. PubMed ID: 31494742
[TBL] [Abstract][Full Text] [Related]
39. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
[TBL] [Abstract][Full Text] [Related]
40. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
